IT201700034630A1 - Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae - Google Patents

Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae

Info

Publication number
IT201700034630A1
IT201700034630A1 IT102017000034630A IT201700034630A IT201700034630A1 IT 201700034630 A1 IT201700034630 A1 IT 201700034630A1 IT 102017000034630 A IT102017000034630 A IT 102017000034630A IT 201700034630 A IT201700034630 A IT 201700034630A IT 201700034630 A1 IT201700034630 A1 IT 201700034630A1
Authority
IT
Italy
Prior art keywords
pad2
diagnosis
prevention
treatment
virus infections
Prior art date
Application number
IT102017000034630A
Other languages
English (en)
Inventor
Santo Landolfo
Francesca Gugliesi
Valentina Dell'oste
Sara Pautasso
Andrea Marco De
Gloria Griffante
Original Assignee
Univ Degli Studi Di Torino
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Degli Studi Di Torino filed Critical Univ Degli Studi Di Torino
Priority to IT102017000034630A priority Critical patent/IT201700034630A1/it
Priority to PCT/IB2018/052204 priority patent/WO2018178935A1/en
Priority to EP18720365.8A priority patent/EP3600386A1/en
Publication of IT201700034630A1 publication Critical patent/IT201700034630A1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IT102017000034630A 2017-03-29 2017-03-29 Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae IT201700034630A1 (it)

Priority Applications (3)

Application Number Priority Date Filing Date Title
IT102017000034630A IT201700034630A1 (it) 2017-03-29 2017-03-29 Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae
PCT/IB2018/052204 WO2018178935A1 (en) 2017-03-29 2018-03-29 Pad2 for use in preventing and/or treating or diagnosing infections caused by viruses of the herpesviridae family
EP18720365.8A EP3600386A1 (en) 2017-03-29 2018-03-29 Pad2 for use in preventing and/or treating or diagnosing infections caused by viruses of the herpesviridae family

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT102017000034630A IT201700034630A1 (it) 2017-03-29 2017-03-29 Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae

Publications (1)

Publication Number Publication Date
IT201700034630A1 true IT201700034630A1 (it) 2018-09-29

Family

ID=59683753

Family Applications (1)

Application Number Title Priority Date Filing Date
IT102017000034630A IT201700034630A1 (it) 2017-03-29 2017-03-29 Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae

Country Status (3)

Country Link
EP (1) EP3600386A1 (it)
IT (1) IT201700034630A1 (it)
WO (1) WO2018178935A1 (it)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569338B (zh) * 2020-07-24 2022-12-23 上海谋始生物科技有限公司 Tdfa在制备预防和/或治疗眼表炎症疾病的药物中的应用
KR20240020754A (ko) * 2022-08-08 2024-02-16 재단법인 아산사회복지재단 Pad 저해제를 포함하는 퇴행성 판막 질환의 예방 또는 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046309A2 (en) * 2002-11-18 2004-06-03 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
WO2014086365A1 (en) * 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004046309A2 (en) * 2002-11-18 2004-06-03 Phoenix Pharmacologics, Inc. Methods for inhibiting viral replication in vivo
WO2014086365A1 (en) * 2012-12-03 2014-06-12 Rigshospitalet Anti-pad2 antibodies and treatment of autoimmune diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BAWADEKAR MANDAR ET AL: "Peptidylarginine deiminase 2 is required for tumor necrosis factor alpha-induced citrullination and arthritis, but not neutrophil extracellular trap formation", JOURNAL OF AUTOIMMUNITY, LONDON, GB, vol. 80, 7 February 2017 (2017-02-07), pages 39 - 47, XP029997133, ISSN: 0896-8411, DOI: 10.1016/J.JAUT.2017.01.006 *
IZZO F ET AL: "Pegylated Arginine Deiminase Treatment of Patients with Unresectable Hepatocellular Carcinoma; Results from Phrase I/II Studies", JOURNAL OF CLINICAL ONCOLOGY, AMERICAN SOCIETY OF CLINICAL ONCOLOGY, US, vol. 22, no. 10, 1 May 2004 (2004-05-01), pages 1815 - 1822, XP002988856, ISSN: 0732-183X, DOI: 10.1200/JCO.2004.11.120 *
M. A. MOSCARELLO ET AL: "Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis", DISEASE MODELS & MECHANISMS, vol. 6, no. 2, 1 November 2012 (2012-11-01), GB, pages 467 - 478, XP055427970, ISSN: 1754-8403, DOI: 10.1242/dmm.010520 *
SANCHEZ MARIA DULFARY ET AL: "Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 132, 15 May 2016 (2016-05-15), pages 13 - 25, XP029676378, ISSN: 0166-3542, DOI: 10.1016/J.ANTIVIRAL.2016.05.009 *

Also Published As

Publication number Publication date
EP3600386A1 (en) 2020-02-05
WO2018178935A1 (en) 2018-10-04

Similar Documents

Publication Publication Date Title
BR112016020199A2 (pt) Composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
CO2021004456A2 (es) Vacunas neumocócicas multivalentes
HUE059149T2 (hu) 2,4-Diaminokinazolin származékok és azok alkalmazása vírusfertõzések, rák vagy allergiák kezelésében
MA47688A (fr) Compositions utiles dans le traitement de l'amyotrophie spinale
BR112013014189A2 (pt) composição farmacêutica que compreende transcinamaldeíco e o uso da mesma no tratamento de infecções
PL3615035T3 (pl) Zastosowanie 20-hydroksyekdyzonu i jego pochodnych w leczeniu miopatii
EP3600305A4 (en) BERBERIN ALKALOID FORMULATIONS FOR THE PREVENTION AND / OR TREATMENT OF INFECTIOUS DISEASES
ES2969239T3 (es) Combinación de ledipasvir y sofosbuvir para su uso en el tratamiento de infecciones por el virus de la hepatitis B en humanos
SG11201809811VA (en) Compositions and methods for treatment of inflammation or infection of the eye
IT201700034630A1 (it) Pad2 per uso nella prevenzione e/o trattamento o diagnosi di infezioni da virus della famiglia herpesviridae
EP3302464A4 (en) USE OF CANNABINOIDS IN THE TREATMENT OF INFLAMMATION AND / OR EYE PAIN
CO2019014647A2 (es) Composiciones inmunogénicas
ZA201906964B (en) Prevention and/or treatment of inflammatory skin disease
ITUA20161865A1 (it) Uso di lentinano per il trattamento e la prevenzione di endometriosi.
FI20165153A (fi) Lyofilisoitu farmaseuttinen formulaatio ja sen käyttö
ES2660372T8 (es) Sustancias y procedimientos para la utilización en la prevención y/o el tratamiento en la enfermedad de Huntington
EP3687629A4 (en) TREATMENT AND DETECTION OF INFECTION AND DISEASE ASSOCIATED WITH DIFFERENT FUNGAL PATHOGENS
CY1119674T1 (el) Θεραπεια και προληψη της νοσου αλτσχαϊμερ (ad)
FR3032616B1 (fr) Compose de la famille des avermectines pour le traitement et/ou la prevention des folliculites
ZA201808182B (en) Composition comprising at least one enzyme and at least one microbicidal molecule for the prevention or treatment of post-implant infections
IT201700109607A1 (it) Composizione per l'uso nella prevenzione e/o nel trattamento del glaucoma.
GB2561945B (en) Tissue stain and use thereof
IL253418A0 (en) Nisin-based compounds and their use in the treatment of bacterial infections
ITUB20169882A1 (it) Vitamina E per l’uso nel trattamento e nella prevenzione delle infezioni da biofilm.
IT201700079581A1 (it) Composizioni comprendenti o costituite da Polidatina per uso nel trattamento delle patologie ossee